ProPhase Labs’ Cancer Therapeutic, Linebacker-1, pre-clinical studies with Dana Farber/Harvard Cancer Institute demonstrate impressive utility and move into next phase of testing Linebacker fully inhibited lung cancer cell growth and significantly limited colon cancer cell growth in two separate clonogenic models Development ahead of schedule with mice studies well underway...

ProPhase Labs’ Linebacker-1 Cancer Therapeutic shows promising mechanisms of action as both a mono-therapy and co-therapy in preclinical studies attacking a range of hard-to-treat cancers, including lung and gastric cancers Garden City, NY, May 03, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase”), a next-generation biotech, genomics and diagnostics company, today provided an update regarding its...